payday loans
payday loans
Skip to content

Accueil
L'essentiel de la littérature réçente en Pneumologie

Dans cette rubrique on vous propose une revue de la littérature à travers une sélection d'abstracts d'articles originaux.
On essaiera de vous tenir informé des dernières nouveautés de recherche en matière de Pneumologie. On ne vous fournit que le résumé de l'article et le lien correspondant, pour accéder à l'article en full text vous devez être inscrits à la revue correspondante.
Cliquez ici pour consulter la liste des revues de Pneumologie disponibles en libre accès.



Epicutaneous Immunotherapy in Grass-Induced Allergic Rhinitis Imprimer Envoyer
Mardi, 30 Novembre 2010 07:11

Epicutaneous Immunotherapy in Grass-Induced Allergic Rhinitis

  • Content Type Journal Article
  • DOI 10.1007/s11882-010-0165-4
  • Authors
    • John J. Oppenheimer, Pulmonary and Allergy Associates, New Jersey Medical School, 8 Saddle Road, Cedar Knolls, NJ 07927, USA
Lire la suite...
 
Diagnosis of Allergy and Asthma in Childhood Imprimer Envoyer
Mardi, 30 Novembre 2010 07:11

Abstract  
Childhood asthma is a widespread health problem because of its epidemic prevalence, as asthma affects more than 300 million people worldwide. Results from cross-sectional and cohort studies show that asthma starts in childhood in a large proportion of cases. A proper diagnosis is easier to make in adults and school-age children, as permanent changes in lung development, the strong impact of environmental factors on the airways, the immunologic maturity process, and the use of some diagnostic tools make asthma more difficult to diagnose in preschool children. This period of a child’s life is an interesting challenge for pediatricians and specialists. The aim of the present review is to analyze the current knowledge regarding making an early and accurate asthma diagnosis and therefore deciding on the correct treatment to gain control over asthma symptoms and minimize health risks.

  • Content Type Journal Article
  • DOI 10.1007/s11882-010-0156-5
  • Authors
    • Carlos E. Baena-Cagnani, CIMER (Centro de Investigación en Medicina Respiratoria), Catholic University of Córdoba, Santa Rosa 381, X 5000 ESG, Córdoba, Argentina
    • Héctor A. Badellino, CIMER (Centro de Investigación en Medicina Respiratoria), Catholic University of Córdoba, Santa Rosa 381, X 5000 ESG, Córdoba, Argentina
Lire la suite...
 
Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment. Imprimer Envoyer
Mardi, 30 Novembre 2010 07:06
Related Articles

Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment.

Oncology. 2010 Nov 12;79(1-2):78-84

Authors: Kim ST, Lee J, Sun JM, Park YH, Ahn JS, Park K, Ahn MJ

Purpose: To devise a prognostic model based on clinical parameters for non-small cell lung cancer (NSCLC) patients treated with erlotinib as a salvage therapy. Patients and Methods: Between July 2006 and September 2008, two hundred fifty-seven metastatic/relapsed NSCLC patients who had been treated with erlotinib as a salvage therapy were analyzed retrospectively. Results: For the 257 patients, the median overall survival (OS) and progression-free survival (PFS) with erlotinib treatment were 12.4 and 2.8 months. Multivariate analysis showed that an ECOG performance status of 2 or more, an elevated serum LDH level, and the absence of skin rash were independent adverse prognostic factors for OS and that the presence of intra-abdominal metastasis, 2 or more prior chemotherapy regimens, and the absence of skin rash were prognostic factors for PFS. Patients were categorized into the following 4 prognosis groups on the basis of each adverse prognostic factor: good, intermediate, poor, and very poor prognosis. The median OS times for the good, intermediate, poor, and very poor prognosis groups were 22.0, 9.3, 5.4, and 2.7 months (p < 0.001) and the median PFS times were 6.5, 3.0, 1.2, and 0.9 months (p < 0.001). Conclusion: This prognostic model based on clinical parameters would be useful to identify patients who might be most likely to benefit from erlotinib therapy in clinical practice.

PMID: 21071994 [PubMed - as supplied by publisher]

Lire la suite...
 
<< Début < Précédent 3281 3282 3283 3284 3285 3286 3287 3288 3289 3290 Suivant > Fin >>

Page 3285 sur 3290

find-us-on-facebook-2

United4LungHealth

image001

waw15-clr-logo2

WCD2015



PubMed Logo
Word

 To: 

Langtolang Dictionary

CNP2014Ebook

50x50_firefoxsafari_iconGchrome


Notre site est optimisé pour les Navigateurs suivants : Firefox, Safari et Google Chrome. Cliquez sur l'un des logos ci-dessus pour le télécharger et l'installer gratuitement.

Tabac

Accueil Top